Alterations in the basal ganglia in patients with brain tumours may be due to excessive iron deposition

Herynek,Vít; Wagnerová,Dita; Malucelli,Alberto; Vymazal,Josef; Sameš,Martin; Hájek,Milan

doi:10.3892/ol.2014.2638

Alterations in the basal ganglia in patients with brain tumours may be due to excessive iron deposition

Authors:
- Vít Herynek
- Dita Wagnerová
- Alberto Malucelli
- Josef Vymazal
- Martin Sameš
- Milan Hájek
View Affiliations

Affiliations: Department of Diagnostic and Interventional Radiology, Institute for Clinical and Experimental Medicine, Vídeňská, Prague 14021, Czech Republic, Department of Neurosurgery, JE Purkyně University and Masaryk Hospital, Sociální péče, Ústí nad Labem 40113, Czech Republic, Department of Radiology, Na Homolce Hospital, Roentgenova, Prague 15030, Czech Republic
Published online on: October 24, 2014 https://doi.org/10.3892/ol.2014.2638
Pages: 43-46

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The accumulation of iron in the brain is a common physiological process. However, alterations in the deposition of iron or other paramagnetic substances are associated with various diseases. In the present study, the deposition of paramagnetic substances in patients with brain tumours was evaluated using T2 relaxometry. A total of 23 patients with untreated tumours or with recurrent tumours following treatment, together with a group of 19 age‑matched healthy controls, were examined using T2 relaxometry at 3T. The relaxation times in the basal ganglia, thalamus and white matter were evaluated. Significantly lower T2 relaxation times were identified in the basal ganglia and thalamus of the patients with tumours, as compared with those of the controls (P<0.05). No statistically significant difference was identified between patients with untreated or recurrent brain tumours. The reduction in T2 relaxation times in the brain tumour patients was possibly caused by the accumulation of iron, since iron homeostasis is known to be altered in patients with tumours. We propose that increased iron deposition is a consequence of a higher risk of oxidative stress caused by an increased iron concentration in the plasma or cerebrospinal fluid.

View Figures

View References

1	Hallgren B and Sourander P: The effect of age on the non-haemin iron in the human brain. J Neurochem. 3:41–51. 1958. View Article : Google Scholar : PubMed/NCBI
2	Vymazal J, Babis M, Brooks RA, Filip K, Dezortova M, Hrncarkova H and Hajek M: T1 and T2 alterations in the brains of patients with hepatic cirrhosis. AJNR Am J Neuroradiol. 17:333–336. 1996.PubMed/NCBI
3	Wolozin B and Golts N: Iron and Parkinson’s disease. Neuroscientist. 8:22–32. 2002. View Article : Google Scholar : PubMed/NCBI
4	Correia S, Hubbard E, Hassenstab J, et al: Basal ganglia MR relaxometry in obsessive-compulsive disorder: T2 depends upon age of symptom onset. Brain Imaging Behav. 4:35–45. 2010. View Article : Google Scholar : PubMed/NCBI
5	Hájek M, Adamovičová M, Herynek V, Škoch A, Jírů F, Krepelová A and Dezortová M: MR relaxometry and 1H MR spectroscopy for the determination of iron and metabolite concentrations in PKAN patients. Eur Radiol. 15:1060–1068. 2005. View Article : Google Scholar
6	Toyokuni S: Iron-induced carcinogenesis: The role of redox regulation. Free Radic Biol Med. 20:553–566. 1996. View Article : Google Scholar : PubMed/NCBI
7	Evans AE, D’Angio GJ, Propert K, Anderson J and Hann HW: Prognostic factor in neuroblastoma. Cancer. 59:1853–1859. 1987. View Article : Google Scholar : PubMed/NCBI
8	Potaznik D, Groshen S, Miller D, Bagin R, Bhalla R, Schwartz M and de Sousa M: Association of serum iron, serum transferrin saturation and serum ferritin with survival in acute lymphocytic-leukemia. Am J Pediat Hematol Oncol. 9:350–355. 1987. View Article : Google Scholar
9	Richmond HG: Induction of sarcoma in the rat by iron-dextran complex. Br Med J. 1:947–949. 1959. View Article : Google Scholar : PubMed/NCBI
10	Huang X: Iron overload and its association with cancer risk in humans: evidence for iron as a carcinogenic metal. Mutat Res. 533:153–171. 2003. View Article : Google Scholar : PubMed/NCBI
11	Sato Y, Honda Y, Asoh T, Oizumi K, Ohshima Y and Honda E: Cerebrospinal fluid ferritin in glioblastoma: evidence for tumor synthesis. J Neurooncol. 40:47–50. 1998. View Article : Google Scholar
12	Richardson DR, Kalinowski DS, Lau S, Jansson PJ and Lovejoy DB: Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents. Biochim Biophys Acta. 1790:702–717. 2009. View Article : Google Scholar
13	Vymazal J, Urgosík D and Bulte JW: Differentiation between hemosiderin- and ferritin-bound brain iron using nuclear magnetic resonance and magnetic resonance imaging. Cell Mol Biol (Noisy-le-grand). 46:835–842. 2000.
14	Schenker C, Meier D, Wichmann W, Boesiger P and Valavanis A: Age distribution and iron dependency of the T2 relaxation time in the globus pallidus and putamen. Neuroradiology. 35:119–124. 1993. View Article : Google Scholar : PubMed/NCBI
15	Herynek V, Wagnerová D, Hejlová I, Dezortová M and Hájek M: Changes in the brain during long-term follow-up after liver transplantation. J Magn Reson Imaging. 35:1332–1337. 2012. View Article : Google Scholar : PubMed/NCBI
16	Dusek P, Jankovic J and Le W: Iron dysregulation in movement disorders. Neurobiol Dis. 46:1–18. 2012. View Article : Google Scholar : PubMed/NCBI
17	Steegmann-Olmedillas JL: The role of iron in tumour cell proliferation. Clin Transl Oncol. 13:71–76. 2011. View Article : Google Scholar : PubMed/NCBI
18	Deugnier Y: Iron and liver cancer. Alcohol. 30:145–150. 2003. View Article : Google Scholar : PubMed/NCBI
19	Jian J, Yang Q, Dai J, Eckard J, Axelrod D, Smith J and Huang X: Effects of iron deficiency and iron overload on angiogenesis and oxidative stress - a potential dual role for iron in breast cancer. Free Radic Biol Med. 50:841–847. 2011. View Article : Google Scholar : PubMed/NCBI
20	Richardson DR: Iron chelators as therapeutic agents for the treatment of cancer. Crit Rev Oncol Hematol. 42:267–281. 2002. View Article : Google Scholar : PubMed/NCBI